Skip to content
Peptigraph home

Tirzepatide for Sleep Apnea: What the Evidence Shows

What human and animal studies show about Tirzepatide for sleep apnea, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / GIP dual agonistUpdated
Strongest evidence
Human RCT
Human studies
1
with an outcome for sleep apnea, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for sleep apnea, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
1
with an outcome for sleep apnea

Evidence for sleep apnea

Each row is an outcome related to sleep apnea from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Tirzepatide for sleep apnea: outcomes in published studies
OutcomeResultStudy typeSource
Apnea-hypopnea index, trial 1 (no PAP)Trial 1: AHI fell by 25.3 events per hour with tirzepatide versus 5.3 with placebo at week 52.Human RCTThe New England journal of medicine 2024, PMID 38912654
Apnea-hypopnea index, trial 2 (on PAP)Trial 2: AHI fell by 29.3 events per hour with tirzepatide versus 5.5 with placebo at week 52.Human RCTThe New England journal of medicine 2024, PMID 38912654

Tirzepatide and sleep apnea are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 38912654

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Sleep apnea and the one indication that matches

MedlinePlus says the most common type is obstructive sleep apnea, in which the airway collapses or becomes blocked during sleep; it also notes that not everyone who snores has sleep apnea.[2]

Zepbound is labelled for moderate to severe obstructive sleep apnea in adults with obesity.[3]

The label's OSA dosing line is 10 mg or 15 mg injected subcutaneously once weekly, quoted here as labelling and not as a recommendation.[3]

SURMOUNT-OSA: what the trials measured

Two phase 3 trials enrolled adults with moderate-to-severe OSA and obesity; the primary end point was the change in the apnea-hypopnea index, the number of breathing events per hour of sleep.[1]

In trial 1 the AHI fell by 25.3 events per hour on tirzepatide and 5.3 on placebo, a treatment difference of 20.0 events per hour.[1]

In trial 2 the AHI fell by 29.3 events per hour versus 5.5 on placebo, a difference of 23.8 events per hour.[1]

Secondary outcomes also improved: hypoxic burden, hsCRP, systolic blood pressure and patient-reported sleep outcomes.[1]

What the label adds for people with OSA

The Zepbound label describes two sleep apnea studies: Study 5 enrolled 234 patients unable or unwilling to use PAP therapy, and Study 6 enrolled 235 patients who were on PAP therapy.[3]

Other peptides people research for sleep apnea

No other peptide in our index has a sleep apnea page yet.

Common questions

Does Tirzepatide help with sleep apnea?

The strongest study we summarise for sleep apnea is human rct evidence, across 1 study with an outcome for sleep apnea. A trial result is not an approval; see the legal status.

Is Tirzepatide approved for sleep apnea?

Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.

Does tirzepatide treat sleep apnea?

Zepbound is labelled to treat moderate to severe obstructive sleep apnea in adults with obesity.[3]

Does tirzepatide stop snoring?

The trials cited here measured the apnea-hypopnea index rather than snoring, and MedlinePlus notes that not everyone who snores has sleep apnea.[2]

How much does tirzepatide reduce sleep apnea events?

In trial 1 the AHI fell by 25.3 events per hour on tirzepatide and 5.3 on placebo, and in trial 2 by 29.3 versus 5.5.[1]

Can I stop using my CPAP on tirzepatide?

The label describes studies in people who could not use PAP and in people already on it. It does not address stopping PAP.[3]

More on Tirzepatide

Sources

  1. 1Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.The New England journal of medicine · 2024PMID 38912654Accessed 2 Oct 2026
  2. 2Official web pageOfficial web page · web page
  3. 3ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.